UPDATED May 22, 2024
Companys with strong funding and high growth potential
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
BOVN.F | kr4.70 | 0% | n/a | kr2.7b | kr12.58 | PS9.2x | E62.0% | n/a | Pharmaceuticals & Biotech | ||
0RV2 | kr224.00 | -5.1% | -30.9% | kr19.7b | kr367.84 | PS78.1x | E63.0% | 0% | Pharmaceuticals & Biotech | ||
SGEN | US$228.74 | 4.5% | 76.5% | US$43.2b | US$228.91 | PS18.8x | E71.8% | n/a | Pharmaceuticals & Biotech | ||
0A8R | US$228.95 | 4.6% | 81.1% | US$43.2b | US$229.12 | PS18.8x | E71.8% | n/a | Pharmaceuticals & Biotech | ||
IMGN | US$31.23 | 6.6% | 617.9% | US$8.4b | US$28.95 | PS29.1x | E45.8% | n/a | Pharmaceuticals & Biotech | ||
IPHY.F | €2.20 | 0% | n/a | €206.6m | €5.40 | PS3.4x | E33.0% | n/a | Pharmaceuticals & Biotech | ||
IVVD | US$2.16 | -12.2% | 30.9% | US$263.5m | US$9.23 | PB1.4x | E69.8% | n/a | Pharmaceuticals & Biotech | ||
0A8K | US$31.24 | 6.4% | 658.3% | US$8.4b | US$29.16 | PS29.1x | E45.9% | n/a | Pharmaceuticals & Biotech | ||
0EVI | €2.72 | 16.2% | 1.4% | €221.5m | €6.23 | PS3.6x | E33.0% | n/a | Pharmaceuticals & Biotech | ||
ARDX | US$7.82 | -0.4% | 122.8% | US$1.8b | US$13.83 | PS11.5x | E60.7% | n/a | Pharmaceuticals & Biotech | ||
BRCT.F | kr21.70 | 14.9% | n/a | kr19.7b | kr35.63 | PS78.1x | E63.0% | 0% | Pharmaceuticals & Biotech | ||
IPHA | €3.00 | 19.7% | 3.4% | €221.5m | €6.86 | PS3.6x | E33.0% | n/a | Pharmaceuticals & Biotech | ||
ISEE | US$39.95 | 0.9% | 236.3% | US$5.5b | US$40.00 | PB11.6x | E59.0% | n/a | Pharmaceuticals & Biotech | ||
IVBI.Y | HK$19.48 | 0% | n/a | HK$62.2b | HK$28.32 | PS9.2x | E50.8% | n/a | Pharmaceuticals & Biotech | ||
CSPH.F | HK$0.12 | 0% | n/a | HK$1.8b | n/a | PS3.6x | E56.9% | n/a | Pharmaceuticals & Biotech | ||
TVTX | US$6.56 | -3.5% | -60.9% | US$503.2m | US$14.86 | PS3.2x | E67.7% | n/a | Pharmaceuticals & Biotech | ||
CLRB | US$3.20 | -4.8% | 109.2% | US$116.5m | US$15.00 | PB12.6x | E61.8% | n/a | Pharmaceuticals & Biotech | ||
RCEL | US$8.53 | 4.0% | -21.3% | US$210.1m | US$23.44 | PS4.3x | E60.2% | n/a | Pharmaceuticals & Biotech | ||
MGTX | US$5.66 | 2.4% | -17.4% | US$353.7m | US$21.20 | PS32x | E56.1% | n/a | Pharmaceuticals & Biotech | ||
MDGL | US$235.06 | 11.0% | -19.6% | US$5.2b | US$363.86 | PB5.9x | E64.3% | n/a | Pharmaceuticals & Biotech | ||
SLNO | US$42.87 | -5.2% | 679.5% | US$1.6b | US$68.14 | PB10.9x | E61.5% | n/a | Pharmaceuticals & Biotech | ||
SPRY | US$8.93 | -1.9% | 17.0% | US$868.2m | US$19.00 | PS86527.5x | E58.7% | n/a | Pharmaceuticals & Biotech | ||
ACAD | US$15.82 | 4.6% | -38.3% | US$2.5b | US$27.16 | PS3.2x | E40.8% | n/a | Pharmaceuticals & Biotech | ||
GTHX | US$4.31 | -8.1% | 52.3% | US$236.8m | US$8.50 | PS2.7x | E48.3% | n/a | Pharmaceuticals & Biotech |